Impact of Molecular Markers on Personalised-Treatment Concepts in Gliomas
نویسنده
چکیده
منابع مشابه
Personalized medicine in oncology. New perspectives in management of gliomas
Studies on genetic and epigenetic mechanisms of carcinogenesis have led to the discovery of crucial genetic events for many of particular malignancies. This was followed by invention of new therapeutic approaches based on molecular mechanisms underlying cancer development and progression that bears the name of personalised medicine. In the case of gliomas, ascertainment of genetic/epigenetic ma...
متن کاملMolecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.
Over the past 10 years, there has been an increasing use of molecular markers in the assessment and management of adult malignant gliomas. Some molecular signatures are used diagnostically to help pathologists classify tumours, whereas others are used to estimate prognosis for patients. Most crucial, however, are those markers that are used to predict response to certain therapies, thereby dire...
متن کاملBiomarkers classification and therapeutic decision-making for malignant gliomas.
OPINION STATEMENT Diffuse gliomas are the most common primary brain tumors, with glioblastoma (GBM) encompassing more than 50 % of all cases. Despite aggressive therapy, patients nearly always succumb to their disease and the survival for patients with GBM is approximately 1 year. During past years, numerous scientific contributions have reshaped the field of neuro-oncology and neuropathology. ...
متن کاملImpact of Propionic Acid on Liver Damage in Rats
Propionic acid (PA) is a short chain fatty acid, a common food preservative and metabolic end product of enteric bacteria in the gut. The present study was undertaken to investigate the effect of PA on liver injury in male rats. Male western albino rats were divided into two groups. The first group served as normal control, the second was treated with PA. The activities of serum hepatospecific ...
متن کاملMolecular Markers for Personalised Approach to Patients with Melanoma
The year 2011 was a breakthrough in melanoma treatment with two new targeted drugs, ipilimumab and vemurafenib, approved after showing overall survival benefit in patients with metastatic melanoma. Vemurafenib was approved only for treatment of patients with activating mutations in BRAF gene. Thus, the detection of activating BRAF mutations, which can be found in ≈50% melanomas, became a standa...
متن کامل